On Wednesday 16 February 2022 at 10:30 CET Orphinic Scientific SA will host a videoconference to present the Year-end Report 2021, followed by a Q&A session.
The webcast can be followed live after prior registration
The presentation from the webcast available HERE
16.02.22_Orphinic Scientific Podumowanie_2021
16.02.2022 OSYeSummary 2021 ENG
Information on Orphinic Scientific SA reporting
The Orphinic Scientific SA has a long-term business model founded on a promise to its investors to drive value creation and create consistent attractive returns over a 3 to 5-year horizon. The Group’s financial model is primarily influenced by the size of its portfolio under management, the performance of individual projects and its ability to recruit and retain top talents.
Contact
Włodzimierz Łoziński, COO +48 601 23 81 42,
Krzysztof Olszewski, Communication & PR +48 883 382 332
About Orphinic Scientific SA
Orphinic Scientific S.A. was founded in 2019 as the first Polish biopharma portfolio platform creating innovative solutions for orphan diseases and other indications with significant unmet medical needs in the clinical trial phase.
Orphinic core scientific team consists of experts with over 20 years of experience in clinical development processes and their commercialization. The company’s competencies in clinical stage development are further enforced through a collaboration with a large clinical CRO operating in the CEE region. This facilitates access to diverse patient populations and rapid enrollment to clinical trials supporting our projects and significantly shortens the duration of individual phases.
Orphinic currently has 8 projects in the pipeline that range from a preclinical phase to market approval stages in three healthcare segments: therapeutics, medtech and e-health.
